DIVISLAB2023-10-012023-12-31 DIVISLAB2023-10-012023-12-31 DIVISLAB2023-10-012023-12-31in-bse-fin:OneOperatingExpenses01Member DIVISLAB2023-10-012023-12-31in-bse-fin:FourOperatingExpenses01Member DIVISLAB2023-12-31 DIVISLAB2023-10-012023-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member DIVISLAB2023-10-012023-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member DIVISLAB2023-10-012023-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member DIVISLAB2023-10-012023-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532488 DIVISLAB NOTLISTED Divi's Laboratories Limited Equity 2023-04-01 2024-03-31 2024-02-10 2024-01-30 INR Crores Third quarter 10:45:00 11:55:00 2024-02-10 2024-02-10 Not applicable Single segment Manufacture of Active Pharmaceutical Ingredients, Intermediates and Nutraceutical ingredients 2023-10-01 2023-12-31 Unaudited Consolidated 18550000000.00 950000000.00 19500000000.00 7940000000.00 0.00 -650000000.00 2680000000.00 0.00 950000000.00 3690000000.00 14610000000.00 4890000000.00 0.00 4890000000.00 1220000000.00 90000000.00 1310000000.00 0.00 3580000000.00 0.00 0.00 0.00 0.00 3580000000.00 50000000.00 3630000000.00 3580000000.00 0.00 3630000000.00 0.00 530000000.00 2 13.50 13.50 0.00 0.00 13.50 13.50 1.The above Statement of consolidated unaudited financial results for the quarter and nine months ended 31st December, 2023, is prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (‘IND AS’), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The financial results were, as reviewed by the Audit Committee, considered and approved by the Board of Directors at its meeting held on 10th February, 2024. The statutory auditors have carried out a limited review of the statement and issued an unmodified report thereon. 2.The consolidated unaudited financial results include the financial results of Divi’s Laboratories Limited and its two subsidiaries Divis Laboratories (USA) Inc. and Divi’s Laboratories Europe AG (Referred as the “Group”). 3.The group is engaged in the manufacture of Active Pharmaceutical ingredients, intermediates, and nutraceutical ingredients and the same constitutes single reportable business segment as per Ind AS 108. 4.The Group does not have any discontinued operations and the Profit for the period represents the Profits from continuing operations only. 5.Forex gain included in Other Income for the respective periods is as given below: Rs. in Crores Quarter ended Nine months ended Year ended 31.12.2023 30.09.2023 31.12.2022 31.12.2023 31.12.2022 31.03.2023 Forex gain 18 11 47 32 134 130 Single segment 2023-04-01 2023-12-31 Unaudited Consolidated 55420000000.00 2620000000.00 58040000000.00 23340000000.00 0.00 -1070000000.00 7970000000.00 10000000.00 2830000000.00 10460000000.00 43540000000.00 14500000000.00 0.00 14500000000.00 3540000000.00 340000000.00 3880000000.00 0.00 10620000000.00 0.00 0.00 0.00 0.00 10620000000.00 70000000.00 10690000000.00 10620000000.00 0.00 10690000000.00 0.00 530000000.00 2 40.02 40.02 0.00 0.00 40.02 40.02 Other Expenses 3690000000.00 Other Expenses 10460000000.00 Gain on Remeasurement of post-employment benefit obligations 10000000.00 Gain on Remeasurement of post-employment benefit obligations 30000000.00 10000000.00 30000000.00 0.00 10000000.00 Exchange differences in translating the financial statements of foreign operations 50000000.00 Exchange differences in translating the financial statements of foreign operations 60000000.00 50000000.00 60000000.00 10000000.00 10000000.00